Robertson CA, et al. Safety and Immunogenicity of a Full-Dose Split-Virion Inactivated Quadrivalent Influenza Vaccine in Healthy Children 6 to 35 Months of Age: A Randomized Controlled Clinical Trial. Pediatr Infect Dis J. 2018 Nov 2
BACKGROUND:
For children aged < 3 years, a half dose of inactivated influenza vaccine (7.5 μg hemagglutinin/strain) has been used for more than 30 years, but several studies indicate that a full dose (15 μg hemagglutinin/strain) can be used in this population without increasing the rate of fever or other reactions. Here we compare the safety and immunogenicity of full and half doses of quadrivalent split-virion inactivated influenza vaccine (IIV4) in children aged 6 to 35 months.
METHODS:
In this phase IV, randomized, observer-blinded, multi-center study, healthy children aged 6 to 35 months were randomized 1:1 to be vaccinated with a half or full dose of IIV4 (NCT02915302). The primary objective was to demonstrate that the rate of any fever (≥ 38.0°C) up to 7 days after a full dose of IIV4 was non-inferior to the rate of fever after a half dose.
RESULTS:
The study included 1950 children. Non-inferiority in the rate of fever was demonstrated for the full dose vs. the half dose of IIV4 (difference in rate = 0.84% [95% confidence interval, -2.13%-3.80%]). Solicited reactions and unsolicited adverse events were similar between the dose groups. No vaccine-related serious adverse events were reported. Non-inferiority of both hemagglutination inhibition geometric mean titers and seroconversion rates was demonstrated for all four vaccine strains for the full dose vs. the half dose.
CONCLUSIONS:
In children aged 6 to 35 months, a full dose of IIV4 was immunogenic and had a safety profile comparable to that of a half dose, with no new safety concerns observed.
For children aged < 3 years, a half dose of inactivated influenza vaccine (7.5 μg hemagglutinin/strain) has been used for more than 30 years, but several studies indicate that a full dose (15 μg hemagglutinin/strain) can be used in this population without increasing the rate of fever or other reactions. Here we compare the safety and immunogenicity of full and half doses of quadrivalent split-virion inactivated influenza vaccine (IIV4) in children aged 6 to 35 months.
METHODS:
In this phase IV, randomized, observer-blinded, multi-center study, healthy children aged 6 to 35 months were randomized 1:1 to be vaccinated with a half or full dose of IIV4 (NCT02915302). The primary objective was to demonstrate that the rate of any fever (≥ 38.0°C) up to 7 days after a full dose of IIV4 was non-inferior to the rate of fever after a half dose.
RESULTS:
The study included 1950 children. Non-inferiority in the rate of fever was demonstrated for the full dose vs. the half dose of IIV4 (difference in rate = 0.84% [95% confidence interval, -2.13%-3.80%]). Solicited reactions and unsolicited adverse events were similar between the dose groups. No vaccine-related serious adverse events were reported. Non-inferiority of both hemagglutination inhibition geometric mean titers and seroconversion rates was demonstrated for all four vaccine strains for the full dose vs. the half dose.
CONCLUSIONS:
In children aged 6 to 35 months, a full dose of IIV4 was immunogenic and had a safety profile comparable to that of a half dose, with no new safety concerns observed.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 9 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 9 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 10 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 10 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 10 hours ago
[Go Top] [Close Window]


